Skip to search formSkip to main contentSkip to account menu

tigatuzumab

Known as: Anti-DR5 MoAb, Anti-TRAIL-R2 MoAb, anti-[Homo sapiens TNFRSF10B (Tumor Necrosis Factor Receptor Superfamily Member 10B, DR5, TRAIL-R2, CD262)] Humanized Monoclonal TRA-8 
A humanized agonistic monoclonal antibody directed against human tumor necrosis factor-related apoptosis-inducing ligand receptor 2 (TRAIL-R2) with… 
National Institutes of Health

Related topics

Related topics

6 relations

Broader (1)

Antibodies, Monoclonal, Humanized
Antibody-Dependent Cellular CytotoxicityNCIt Antineoplastic Agent TerminologyTNFRSF10B protein, humanantigen binding

Narrower (1)

CS-1008

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
New Oe Stars in LAMOST DR5
Stars of spectral type Oe are very rare. To date, only 13 Oe stars have been identified within our Galaxy. In this paper, we… 
2016
2016
A Novel Imaging Biomarker Extracted from Fluorescence Microscopic Imaging of TRA-8/DR5 Oligomers Predicts TRA-8 Therapeutic Efficacy in Breast and Pancreatic Cancer Mouse Models
PurposeThe aim of the study was to develop a reliable quantitative imaging biomarker from fluorescence microscopic imaging of TRA… 
Review
2015
Review
2015
Goes On the Offensive The Role of Innate Immunity in Osteoarthritis : When Our First Line of Defense
Although osteoarthritis (OA) has existed since the dawn of humanity, its pathogenesis remains poorly understood. OA is no longer… 
2014
2014
Abstract 2279: Adenine nucleotide translocase-2 is a key molecule in the enhancement of TRAIL sensitivity by flavonoids
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA Tumor necrosis factor-related apoptosis-inducing ligand… 
2013
2013
TBCRC 019: An open label, randomized, phase II trial of nanoparticle albumin-bound paclitaxel (nab-PAC) with or without the anti-death receptor 5 (DR5) monoclonal antibody tigatuzumab (TIG) in…
1052 Background: TIG, an agonistic anti-DR5 monoclonal antibody, triggers apoptosis in DR5+ human tumor cells without the aid of… 
2012
2012
Phase Ib dose-escalation study of a phase II randomized trial to assess the safety and tolerability of tigatuzumab (CS-1008) in combination with sorafenib in patients (pts) with advanced…
e14617 Background: Tigatuzumab (T), a humanized monoclonal antibody that acts as a DR5 agonist and exerts tumor necrosis factor… 
2012
2012
A randomized, double-blind, placebo-controlled phase II study of tigatuzumab (CS-1008) in combination with carboplatin/paclitaxel in patients with chemotherapy-naive metastatic/unresectable non-small…
7536 Background: Tigatuzumab (T), a humanized monoclonal antibody that acts as a DR5 agonist induces apoptosis in human cancer… 
2011
2011
TBCRC 019: An open-label, randomized, phase II trial of nanoparticle albumin-bound paclitaxel with or without the anti-death receptor 5 (DR5) monoclonal antibody tigatuzumab in patients with…
TPS128 Background: TNBC has poor prognosis and with no known therapeutic targets in clinical use. Tigatuzumab is a humanized anti… 
2009
2009
Anti-DR5 mAb诱导佐剂型关节炎大鼠滑膜细胞凋亡及机理初探
目的：探讨Anti-DR5 mAb诱导佐剂型关节炎（Adjuvant Arthritis,AA）大鼠滑膜细胞凋亡作用及其可能机理。方法：注射弗氏完全佐剂建立AA大鼠模型,分离并体外培养大鼠滑膜细胞。MTT检测、DNA倍体分析及流式细胞术分析Anti-DR5… 
2007
2007
The study of anti-DR5 McAb on rats adjuvant arthritis and its mechanisms
Objective To study the therapeutic effects of anti-DR5 McAb on treating rats adjuvant ar- thritis(AA) and its immunoregulatory… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)